Objective: Lysinuric protein intolerance (LPI) is a rare autosomal recessive disorder affecting the transport of cationic amino acids. It has previously been shown that approximately one third of the Finnish LPI patients have impaired renal function. The aim of this study was to analyse in detail urine beta2-microglobulin values, renal dysfunction, oral l-citrulline doses and plasma citrulline concentrations in Finnish LPI patients.
Methods and results: Of the 41 Finnish LPI patients, 56% had proteinuria and 53% hematuria. Mean plasma creatinine concentration was elevated in 48%, serum cystatin C in 62%, and urine beta2-microglobulin in 90% of the patients. Seventeen per cent of the patients developed ESRD, and five of them received a kidney transplant.
l-citrulline doses and fasting plasma citrulline concentrations were similar in adult LPI patients with decreased and normal GFR (mean ± SD 79.5 ± 29.2 vs. 82.4 ± 21.9 mg/kg/day, P = 0.619, and 80.3 ± 20.1 vs. 64.8 ± 23.0 μmol/l, P = 0.362, respectively).
Conclusions: Urine beta2-microglobulin is a sensitive early marker of renal involvement, and it should be monitored regularly in LPI patients. Weight-based oral l-citrulline doses and plasma citrulline concentrations were not associated with renal function. LPI patients with ESRD were successfully treated with dialysis and kidney transplantation.
Glomerular Filtration Rate Serum Cystatin Normal Glomerular Filtration Rate Lysinuric Protein Intolerance Urine Dipstick Test
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
End-stage renal disease
Glomerular filtration rate
Lysinuric protein intolerance
Modification of diet in renal disease
Solute carrier family 7, member 7
y+l amino acid transporter-1
This is a preview of subscription content, log in to check access.
We thank Tero Vahlberg for help in the analysis of the l-citrulline doses.
Perheentupa J, Visakorpi J (1965) Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism. Lancet 2:813–816CrossRefPubMedGoogle Scholar
Norio R, Perheentupa J, Kekomäki M, Visakorpi J (1971) Lysinuric protein intolerance, an autosomal recessive disease. A genetic study of 10 Finnish families. Clin Genet 2:214–222Google Scholar
Rajantie J, Simell O, Perheentupa J (1980a) Basolateral-membrane transport defect for lysine in lysinuric protein intolerance. Lancet 1:1219–1221CrossRefPubMedGoogle Scholar
Borsani G, Bassi MT, Sperandeo MP et al (1999) SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet 21:297–301CrossRefPubMedGoogle Scholar
Torrents D, Mykkänen J, Pineda M et al (1999) Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene. Nat Genet 21:293–296CrossRefPubMedGoogle Scholar
Torrents D, Estévez R, Pineda M et al (1998) Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance. J Biol Chem 273:32437–32445CrossRefPubMedGoogle Scholar
Incerti B, Andria G, Parenti G et al (1993) Lysinuric protein intolerance – studies on 17 Italian patients. Am J Hum Genet 53:908Google Scholar
Koizumi A, Shoji Y, Nozaki J et al (2000) A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate. Japan due to a founder effect. The Mass Screening Group. Hum mutat 16:270–271CrossRefPubMedGoogle Scholar
Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE (1975) Lysinuric protein intolerance. Am J Med 59:229–240CrossRefPubMedGoogle Scholar
Simell O (2001) Lysinuric protein intolerance and other cationic aminoacidurias. In: Scriver CS, Beaucert AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 4933–4956Google Scholar
Tanner L, Niinikoski H, Näntö-Salonen K, Simell O (2010) Combined hyperlipidemia in patients with lysinuric protein intolerance. J Inherit Metab Dis 33:145–150CrossRefGoogle Scholar
Tanner L, Näntö-Salonen K, Rashed MS et al (2008) Carnitine deficiency and l-carnitine supplementation in lysinuric protein intolerance. Metab Clin Exp 57:549–554CrossRefPubMedGoogle Scholar
DiRocco M, Garibotto G, Rossi GA et al (1993) Role of haematological, pulmonary and renal complications in the long-term prognosis of patients with lysinuric protein intolerance. Eur J Pediatr 152:437–440CrossRefPubMedGoogle Scholar
Parto K, Kallajoki M, Aho H, Simell O (1994) Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. Hum Pathol 25:400–407CrossRefPubMedGoogle Scholar
Tanner L, Näntö-Salonen K, Niinikoski H et al (2007) Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance. J Pediatr 150:631–634CrossRefPubMedGoogle Scholar
Creswell P, Springer T, Strominger JL et al (1974) Immunological identity of the small subunit of HLA antigens and b2-microglobulin and its turnover on the cell membrane. Proc Nat Acad Sci USA 71:2123–2207CrossRefGoogle Scholar
Bianchi C, Donadio C, Tramonti G, Consani C, Lorusso P, Rossi G (2001) Reappraisal of serum β2-microglobulin as marker of GFR. Ren Fail 23(3–4):419–429CrossRefPubMedGoogle Scholar
Rajantie J, Simell O, Rapola J, Perheentupa J (1980b) Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine. J Pediatr 97(6):229–240CrossRefGoogle Scholar
Awrich AE, Stackhouse WJ, Cantrell JE, Patterson JH, Rudman D (1975) Hyperdibasicaminoaciduria, hyperammonemia, and growth retardation: Treatment with arginine, lysine, and citrulline. J Pediatr 87:731–738CrossRefPubMedGoogle Scholar
Lukkarinen M, Näntö-Salonen K, Pulkki K, Aalto M, Jahnukainen T, Simell O (2006) Renal Complications in lysinuric protein intolerance. In: Lukkarinen M (ed) Improvements of the treatment in lysinuric protein intolerance. Annales Universitatis Turkuensis. Yliopistopaino, Helsinki, pp 52–80Google Scholar
Sebastio G, Sperandeo MP, Andria G (2011) Lysinuric protein intolerance: reviewing concepts on a multisystem disease. Am J Med Genet C Semin Med Genet 157:54–62CrossRefGoogle Scholar
Mori M (2007) Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J Nutr 137:1616S–1620SPubMedGoogle Scholar
Morris S (2007) Arginine metabolism: boundaries of our knowledge. J Nutr 137:1602S–1609SPubMedGoogle Scholar
Ogier de Baulny H, Schiff M, Dionisi-Vici C (2012) Lysinuric protein intolerance (LPI): a multi organ disease by far more complex than a classic urea cycle disorder. Mol Genet Metab 106:12–17CrossRefPubMedGoogle Scholar